Category: Soft Tissue and Bone Sarcoma Group
Retrospective Analysis of Two EORTC Studies Showed That Gastric Acid Suppressants May Negatively Impact Survival Outcomes in Sarcoma Patients Treated With Pazopanib
EORTC opens trial for patients with high grade undifferentiated uterine sarcoma, a rare cancer
Should first-line treatment for advanced or metastatic soft tissue sarcoma be doxorubicin alone or with ifosfamide?
EORTC analysis characterizes long-term responders and survivors on pazopanib for advanced soft tissue sarcomas